Related Experiment Video
Updated: Feb 23, 2026
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
4.5K
Cholinergic activity and levodopa-induced dyskinesia: a multitracer molecular imaging study
Joachim Brumberg1, Sebastian Küsters2, Ehab Al-Momani1
1Department of Nuclear Medicine University Hospital Würzburg and Julius-Maximilians-University Würzburg Germany.
Annals of Clinical and Translational Neurology
|September 15, 2017
Summary
Levodopa-induced dyskinesias in Parkinson's disease are linked to increased striatal cholinergic activity. This suggests a role for cholinergic signaling in managing dopamine responsiveness and disease progression.
Area of Science:
- Neuroscience
- Neurology
- Pharmacology
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor symptoms due to dopamine deficiency.
- Levodopa is a primary treatment, but its long-term use can lead to levodopa-induced dyskinesias (LID).
- The underlying mechanisms of LID, particularly the role of cholinergic systems, remain incompletely understood.
Purpose of the Study:
- To investigate the association between levodopa-induced dyskinesias (LID) and striatal cholinergic activity in Parkinson's disease patients.
- To explore the relationship between nicotinic acetylcholine receptor density and LID.
- To assess the role of cholinergic signaling in the context of dopaminergic depletion in PD.
Main Methods:
- The study included 13 PD patients with LID, 12 non-dyskinetic PD patients, and 12 healthy controls.
- Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) were used to assess brain metabolism, dopamine transporter density, and nicotinic acetylcholine receptor binding.
- Striatal binding potentials and clinical variables were analyzed for correlations.
Main Results:
- Nicotinic acetylcholine receptor density in the caudate nucleus was similar in dyskinetic PD patients and healthy controls.
- Dyskinetic patients showed significantly higher nicotinic acetylcholine receptor density compared to non-dyskinetic patients, especially on the side contralateral to the most affected motor symptoms.
- No significant differences were found in dopamine transporter density or metabolic activity between groups.
Conclusions:
- The findings support the hypothesis that dyskinesia expression is related to cholinergic neuronal excitability in the dopaminergic-depleted striatum of PD patients.
- Cholinergic signaling appears to play a crucial role in maintaining striatal dopaminergic responsiveness.
- These mechanisms may influence Parkinson's disease phenotype and progression, offering potential therapeutic targets.
Related Concept Videos
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.8K
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
2.0K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
2.0K
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.1K
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
1.1K
01:22Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
2.3K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
2.3K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.7K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.7K
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
2.4K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.4K